Study of Medtronic Hugo™ robotic-assisted surgery system in hernia repair meets safety and effectiveness endpoints
MDT(NYSE:MDT) First-ever investigational device exemption clinical study for robotic-assisted hernia repair in the U.S. presented at the American Hernia Society annual meeting GALWAY, Ireland and NASHVILLE, Tenn., Sept. 4, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT) today announced results from the...
FDA Clears MiniMed™ 780G System to Enable Integration with the Instinct Sensor, Made by Abbott, and Approves Use in Type 2 Diabetes
MDT(NYSE:MDT) GALWAY, Ireland, Sept. 2, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced two U.S. Food and Drug Administration (FDA) regulatory milestones that broaden the MiniMed™ 780G system portfolio: clearance of the SmartGuard™ algorithm as...
Medtronic executives to speak at upcoming investor conferences
MDT(NYSE:MDT) GALWAY, Ireland, Aug. 29, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the following investor conferences: 2025 Wells Fargo Healthcare Conference Thursday, September 4, 2025, at 8:00 a.m. EDT (7:00 a.m....
Medtronic announces Board appointments and shareholder value creation initiatives to advance strategic priorities
MDTExperienced executives John Groetelaars and Bill Jellison appointed to the Board of Directors Board forms new Growth and Operating committees to sharpen focus on the company's ongoing strategic portfolio management, operational execution and capital allocation Plan to host Investor Day in...
Medtronic reports first quarter fiscal 2026 financial results
MDT11th quarter in a row of mid-single digit organic revenue growth; Poised to accelerate growth GALWAY, Ireland, Aug. 19, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its first quarter (Q1) of fiscal year...
Medtronic announces cash dividend for second quarter of fiscal year 2026
MDTGALWAY, Ireland, Aug. 14, 2025 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 14, 2025, approved the company's cash dividend for the second quarter of fiscal year 2026 of $0.71 per ordinary share. This quarterly declaration is consistent with the...
MDT and InvestiFi Partner, Enabling Credit Unions to Offer Modern Digital Investing Capabilities
MDTFARMINGTON HILLS, Mich.--(BUSINESS WIRE)--MDT and InvestiFi partner, enabling credit unions to offer modern digital investing capabilities.
Medtronic Announces MiniMed As Name For Planned New Diabetes Company Following Intended Separation
MDTBreaking Down Medtronic: 4 Analysts Share Their Views
MDTNeedham Reiterates Hold on Medtronicto Hold
MDT'Flexible Tracheostomy Tube Recall: Medtronic Removes Shiley Adult Flexible Tracheostomy Tube with TaperGuard Cuff Reusable Inner Cannula Due to Risk for Disconnection of the Flange from the Device Cannula' - FDA
MDTMizuho Maintains Outperform on Medtronic, Lowers Price Target to $98
MDTRBC Capital Maintains Outperform on Medtronic, Lowers Price Target to $101
MDTBaird Maintains Neutral on Medtronic, Lowers Price Target to $92
MDTNeedham Reiterates Hold on Medtronicto Hold
MDTMedtronic Sees FY2026 Adj EPS $5.50-$5.60 Vs $5.83 Est., Sees 5% Organic Revenue Growth
MDTMedtronic Boosts Quarterly Dividend By 1.4% To $0.71, Payable July 11
MDTMedtronic Q4 Adj. EPS $1.62 Beats $1.58 Estimate, Sales $8.93B Beat $8.82B Estimate
MDTMedtronic Announced Its Intent To Separate Its Diabetes Business Into A New Standalone Company
MDTA Preview Of Medtronic's Earnings
MDT5 Analysts Assess Medtronic: What You Need To Know
MDTNeedham Reiterates Hold on Medtronicto Hold
MDTReported Saturday, Medtronic's Hugo RAS System Achieves 98.5% Surgical Success Rate In Largest U.S. Robotic-Assisted Urology Study
MDTReported Saturday, Medtronic's Affera Sphere-360 Catheter Demonstrates Safety And Performance Results For Paroxysmal AFib
MDTMedtronic Receives U.S FDA Approval For The Omniasecure Defibrillation Lead For Placement Within The Right Ventricle
MDTMedtronic Announces It Has Submitted 510(K) Applications To U.S. Food And Drug Administration Seeking Clearance For An Interoperable Pump
MDTOrchestra BioMed Secures FDA Breakthrough Device Designation For AVIM Therapy, Targeting 7.7M U.S. Patients With Uncontrolled Hypertension
MDTReported Saturday, Medtronic's MiniMed 780G System Gains FDA Clearance For Simplera Sync, Offering Users Greater Flexibility And Innovation
MDTTruist Securities Maintains Hold on Medtronic, Lowers Price Target to $90
MDTLooking Into Medtronic's Recent Short Interest
MDTReported Sunday, Medtronic Evolut TAVR Demonstrates Sustained Valve Performance And Lower Cardiovascular Mortality Trend At 5 Years
MDTFDA Says Medtronic Removes Unused 027 Compatible Pipeline Vantage Embolization Device With Shield Technology; Medtronic Updates Use Instructions For 021 Compatible Pipeline Vantage Embolization Devices; Medtronic Updates Instructions For Using Pipeline Va
MDTReported Sunday, Medtronic Evolut TAVR Demonstrates Superior Durability And Valve Function In Small Annulus Patients, SMART Trial Shows
MDTAnalyst Expectations For Medtronic's Future
MDTCitigroup Upgrades Medtronic to Buy, Raises Price Target to $107
MDTFDA Approves Medtronic's Adaptive Deep Brain Stimulation System For Parkinson's Patients
MDTThe FDA approved Medtronic's BrainSense Adaptive DBS and Electrode Identifier for Parkinson's, enhancing therapy personalization and clinic efficiency.
Medtronic Earns U.S. FDA Approval For The World's First Adaptive Deep Brain Stimulation System For People With Parkinson's
MDTRBC Capital Reiterates Outperform on Medtronic, Maintains $105 Price Target
MDTBaird Maintains Neutral on Medtronic, Raises Price Target to $91
MDTNeedham Reiterates Hold on Medtronicto Hold
MDTMedtronic Q3 Earnings: Cardiovascular And Neuroscience Drive Growth, Surgical Revenue Dips, Reaffirms Annual Forecast
MDTMedtronic reported Q3 revenue of $8.29 billion, missing estimates, while EPS of $1.39 topped forecasts. The company reaffirmed its FY25 organic growth guidance.
CORRECTION: Medtronic Affirms FY25 Adj EPS Outlook of $5.44-$5.50 vs $5.45 Estimate; Narrows FY25 Sales Guidance from $33.46B-$33.63B To $33.46B-$33.59B vs $33.54B Estimate
MDTMedtronic Reaffirms Its FY25 Adjusted EPS Guidance Of $5.44-$5.50 Versus Consensus Of $5.84
MDTMedtronic Reaffirms Its FY25 Organic Revenue Growth Guidance Of 4.75%-5%
MDTMedtronic Q3 2025 Adj EPS $1.39 Beats $1.36 Estimate, Sales $8.29B Miss $8.32B Estimate
MDTMedtronic Unusual Options Activity For February 14
MDTThe Analyst Verdict: Medtronic In The Eyes Of 5 Experts
MDTMedtronic Acquires Nanovis Nano Surface Technology Assets And Rights Related To Sites Medical's OsteoSync For PEEK Interbody Fusion Devices; Terms Not Disclosed
MDTNeedham Reiterates Hold on Medtronicto Hold
MDTMedtronic Receives CMS National Coverage Analysis For Symplicity Spyral Renal Denervation System; Expected Completion Date For National Coverage Analysis Is Oct 11
MDT